PeptiDex
Peptide Research Index
Research-backed
Peptide Research Index
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
Also: Egrifta
💉GHRH AnalogStimulates GH for fat metabolism. Binds to GHRH receptors on the pituitary gland to stimulate natural growth hormone production, specifically targeting visceral adipose tissue.
Falutz et al. (JAMA): Randomized, double-blind, placebo-controlled Phase 3 trial showing 15.2% reduction in visceral adipose tissue vs. 5% increase in placebo. FDA-approved indication.
very strongFalutz et al. (J. Clin. Endocrinol. Metab.): 52-week data confirming sustained 18% visceral fat reduction with continuous therapy, with reversal upon discontinuation.
strongStanley et al. (Ann. Intern. Med.): RCT demonstrating tesamorelin reduces hepatic fat content in HIV-infected patients with abdominal fat accumulation.
strongBaker et al.: GHRH treatment (tesamorelin) shows favorable effects on executive function and verbal memory in cognitively normal and mildly impaired older adults via IGF-1 elevation.
moderatePhase 3 trial showing ~80% increase in IGF-1 levels, improved body image distress scores, and significant trunk fat reduction across multiple patient populations.
strongFDA-approved for lipodystrophy; GI side effects possible. Contraindicated in active malignancy.
⚠️ For educational purposes only. Not medical advice. Consult a healthcare professional before using any peptide.
FDA-approved dose: 2mg SubQ daily. Prescription required.
Last updated: 2026-01 · Laws change frequently. Verify current status in your jurisdiction.
Weeks 2-4
Early GH-related effects; initial fluid retention possible
Month 2-3
Measurable visceral fat reduction (avg 15% in FDA trial at this point)
Long-term
Sustained visceral fat reduction and metabolic improvement; IGF-1 normalization
| Side Effect | Incidence | Severity |
|---|---|---|
Fluid retention From Phase 3 Egrifta trial data | ~15% of users | mild |
Injection site reactions | ~12% of users | mild |
Joint pain / arthralgia | ~8% of users | mild |
Glucose elevation Monitor blood glucose; especially if pre-diabetic | ~5% of users | moderate |
Incidence rates sourced from published clinical trial data where available; otherwise based on community research observations.
Maximize fat loss while preserving or building lean muscle the gold standard for total body transformation
Improve metabolic health, insulin sensitivity, and cellular energy production
Weekly Peptide Research
New studies · vendor alerts · protocol tips
No spam. Unsubscribe anytime. Research use only.